Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025
A Transformative AI Backdrop
Artificial intelligence is driving a disruptive shift in how new medicines are discovered, tested, and delivered. In just the past month, AstraZeneca (AZN) signed a drug discovery agreement worth up to $5.3 billion USD with China-based CSPC Pharmaceutical Group to co-develop pre-clinical drug candidates powered by AI. As this global momentum accelerates, Rakovina Therapeutics is harnessing the power of machine learning at the frontier of oncology - advancing novel cancer therapies that integrate AI-driven discovery, cutting-edge chemistry, and translational science. Read More
Artificial intelligence is driving a disruptive shift in how new medicines are discovered, tested, and delivered. In just the past month, AstraZeneca (AZN) signed a drug discovery agreement worth up to $5.3 billion USD with China-based CSPC Pharmaceutical Group to co-develop pre-clinical drug candidates powered by AI. As this global momentum accelerates, Rakovina Therapeutics is harnessing the power of machine learning at the frontier of oncology - advancing novel cancer therapies that integrate AI-driven discovery, cutting-edge chemistry, and translational science. Read More
Recent Posts
Kosovo Votes in Election Aimed at Breaking Political Deadlock
‘The past gives comfort’: Finding refuge on analog islands amid deepening digital seas
Senvest Capital Inc. Announces Death of Chief Executive Officer and Chairman of the Board
Brazilian judge puts coup plot convicts under house arrest after former police commander flees
US Lukoil Gas Station Owners Left in Limbo Over Russia Sanctions
What’s in the mix, and what’s at risk, for 2026: FP Video
In orbit: Canada’s satellite-to-cell offerings poised to grow after Rogers beta trial
Inside the failed green revolutions at BP and Shell
Zelenskiy Prepares for Trump Meeting as Russia Bombards Kyiv
Sure, the newspaper informed. But as it fades, those who used it for other things must adjust, too
